These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20134266)

  • 21. Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: Results from a single-center Taiwanese study.
    Ku FC; Wu RC; Yang LY; Tang YH; Chang WY; Yang JE; Wang CC; Jung SM; Lin CT; Chang TC; Chao A; Lai CH
    J Formos Med Assoc; 2018 Feb; 117(2):117-125. PubMed ID: 28389144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical Comparison of Ovarian and Uterine Endometrioid Carcinoma, Endometrioid Carcinoma With Clear Cell Change, and Clear Cell Carcinoma.
    Lim D; Ip PP; Cheung AN; Kiyokawa T; Oliva E
    Am J Surg Pathol; 2015 Aug; 39(8):1061-9. PubMed ID: 25871622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.
    Kim A; Enomoto T; Serada S; Ueda Y; Takahashi T; Ripley B; Miyatake T; Fujita M; Lee CM; Morimoto K; Fujimoto M; Kimura T; Naka T
    Int J Cancer; 2009 Nov; 125(10):2316-22. PubMed ID: 19598262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.
    Tsuchiya A; Sakamoto M; Yasuda J; Chuma M; Ohta T; Ohki M; Yasugi T; Taketani Y; Hirohashi S
    Am J Pathol; 2003 Dec; 163(6):2503-12. PubMed ID: 14633622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Napsin A is frequently expressed in clear cell carcinoma of the ovary and endometrium.
    Iwamoto M; Nakatani Y; Fugo K; Kishimoto T; Kiyokawa T
    Hum Pathol; 2015 Jul; 46(7):957-62. PubMed ID: 25971546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of paired box genes 8 and 2 expression in epithelium tissues and the related tumors].
    Song Y; Huang X; Shen GH; Liu XY; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):424-428. PubMed ID: 28635231
    [No Abstract]   [Full Text] [Related]  

  • 27. EphA8 is a prognostic marker for epithelial ovarian cancer.
    Liu X; Xu Y; Jin Q; Wang W; Zhang S; Wang X; Zhang Y; Xu X; Huang J
    Oncotarget; 2016 Apr; 7(15):20801-9. PubMed ID: 26989075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sox10 expression in ovarian epithelial tumors is associated with poor overall survival.
    Kwon AY; Heo I; Lee HJ; Kim G; Kang H; Heo JH; Kim TH; An HJ
    Virchows Arch; 2016 May; 468(5):597-605. PubMed ID: 26951260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix.
    Ota Y; Koizume S; Nakamura Y; Yoshihara M; Takahashi T; Sato S; Myoba S; Ohtake N; Kato H; Yokose T; Miyagi E; Miyagi Y
    Oncol Rep; 2021 Mar; 45(3):1023-1032. PubMed ID: 33650653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
    Brunette LL; Mhawech-Fauceglia PY; Ji L; Skeate JG; Brand HE; Lawrenson K; Walia S; Chiriva-Internati M; Groshen S; Roman LD; Kast WM; Da Silva DM
    BMC Cancer; 2018 Oct; 18(1):970. PubMed ID: 30309325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thyroid transcription factor 1 expression in ovarian carcinomas is an independent prognostic factor.
    Fujiwara S; Nawa A; Nakanishi T; Shimoyama Y; Kajiyama H; Shibata K; Ino K; Nakamura S; Kikkawa F; Yatabe Y
    Hum Pathol; 2010 Apr; 41(4):560-5. PubMed ID: 20004952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?
    Kajiyama H; Mizuno M; Shibata K; Umezu T; Suzuki S; Yamamoto E; Mitsui H; Sekiya R; Niimi K; Kawai M; Nagasaka T; Kikkawa F
    Eur J Obstet Gynecol Reprod Biol; 2014 Oct; 181():305-10. PubMed ID: 25203309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calpain system protein expression and activity in ovarian cancer.
    Zhang S; Deen S; Storr SJ; Chondrou PS; Nicholls H; Yao A; Rungsakaolert P; Martin SG
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):345-361. PubMed ID: 30448882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypoxia-inducible protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma and potential target for molecular therapy.
    Togashi A; Katagiri T; Ashida S; Fujioka T; Maruyama O; Wakumoto Y; Sakamoto Y; Fujime M; Kawachi Y; Shuin T; Nakamura Y
    Cancer Res; 2005 Jun; 65(11):4817-26. PubMed ID: 15930302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Application Value of HNF-1β Transcription Factor in the Diagnosis of Ovarian Clear Cell Carcinoma.
    Huang W; Cheng X; Ji J; Zhang J; Li Q
    Int J Gynecol Pathol; 2016 Jan; 35(1):66-71. PubMed ID: 26166716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clear cell carcinomas of the ovary: a multi-institutional study of 129 cases in Korea with prognostic significance of Emi1 and Galectin-3.
    Min KW; Park MH; Hong SR; Lee H; Kwon SY; Hong SH; Joo HJ; Park IA; An HJ; Suh KS; Oh HK; Yoo CW; Kim MJ; Chang HK; Jun SY; Yoon HK; Chang ED; Kim DW; Kim I;
    Int J Gynecol Pathol; 2013 Jan; 32(1):3-14. PubMed ID: 23202783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice.
    Matsuo Y; Tashiro H; Yanai H; Moriya T; Katabuchi H
    Med Mol Morphol; 2015 Sep; 48(3):146-54. PubMed ID: 25398420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.